APA (7th ed.) Citation

Ross, P., Hendlisz, A., Ajithkumar, T., Iwuji, C., Harris, M., Croagh, D., . . . Wasan, H. (2020). O-1 PanCO: Updated results of an open-label, single-arm pilot study of OncoSil P-32 microparticles in unresectable locally advanced pancreatic adenocarcinoma (LAPC) with gemcitabine + nab-paclitaxel or FOLFIRINOX chemotherapy. Annals of Oncology, 31, 232. https://doi.org/10.1016/j.annonc.2020.04.054

Chicago Style (17th ed.) Citation

Ross, P., et al. "O-1 PanCO: Updated Results of an Open-label, Single-arm Pilot Study of OncoSil P-32 Microparticles in Unresectable Locally Advanced Pancreatic Adenocarcinoma (LAPC) with Gemcitabine + Nab-paclitaxel or FOLFIRINOX Chemotherapy." Annals of Oncology 31 (2020): 232. https://doi.org/10.1016/j.annonc.2020.04.054.

MLA (9th ed.) Citation

Ross, P., et al. "O-1 PanCO: Updated Results of an Open-label, Single-arm Pilot Study of OncoSil P-32 Microparticles in Unresectable Locally Advanced Pancreatic Adenocarcinoma (LAPC) with Gemcitabine + Nab-paclitaxel or FOLFIRINOX Chemotherapy." Annals of Oncology, vol. 31, 2020, p. 232, https://doi.org/10.1016/j.annonc.2020.04.054.